Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anders Tidblad has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Lars Sävendahl

    Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Division of Paediatric Endocrinology, Karolinska University Hospital, Stockholm, Sweden

    4 shared publications
  • Kerstin Albertsson-Wikland

    Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

    2 shared publications
  • Matteo Bottai

    Unit of Biostatistics, Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    2 shared publications
  • Camilla Borghammar

    Skåne University Hospital, Department of Clinical Sciences, Pediatrics, Pediatric Endocrinology, Lund University, Lund, Sweden

    1 shared publication
  • Claude Marcus

    Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Claude Marcus

    Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Sex and age differences in cortisol levels during glucagon stimulation test in children

    by Camilla Borghammar, Johan Svensson, Anders Tidblad, Maria Elfving

    Background: Previous studies of glucagon stimulation test (GST) in children have shown variable results regarding the utility and reliability of the cortisol response to this test and its correlation with clinical parameters. The aim of this study was to assess cortisol levels at GST and to evaluate how clinical parameters, such as age, sex, pubertal status and Body Mass Index (BMI), correlate to cortisol levels in children. Methods: A retrospective study of children evaluated for short stature with the GST. Cortisol, glucose and growth hormone (GH) levels at GST, as well as clinical parameters (age, sex, pubertal status, BMI), were collected from medical records. A peak cortisol of ≥ 450 nmol/L was used as a cut-off indicative of a sufficient response. Non-parametric tests were applied in the statistical analysis, and linear regression was used to examine factors affecting cortisol max at the GST. Results: In total, 171 children were included; median age 7.8 years (1.0–18.0), 60 (35.1%) female, 23 (13.5%) pubertal. Of all children, 145 (84.8%) achieved a peak cortisol ≥ 450 nmol/L. There was a negative correlation between peak cortisol levels and age (Spearman’s rho − 0.26, p = < 0.001). Peak cortisol levels were higher in females vs. males: 667.5 nmol/L (range 400–995) vs. 602 nmol/L (range 202–1008), p = 0.005. A higher number of boys than girls did not reach the cortisol cut-off value of 450 nmol/L (p = 0.022). The difference in maximum stimulated cortisol levels between the sexes remained after adjusting for age with a linear regression model (β (95% CI) 65.3 (15.9–114.6), p = 0.01). Conclusion: GST is a reliable test of the hypothalamic-pituitary-adrenal (HPA) axis in children. Girls and younger children had higher peak cortisol at GST. The results support a need for sex- and age-dependent reference values for cortisol.


  • Open Access

    Long-term risk of neoplastic events after childhood growth hormone treatment: a population-based cohort study in Sweden

    by Anders Tidblad, Matteo Bottai, Karin E. Smedby, Kerstin Albertsson-Wikland, Lars Sävendahl

    Background: Increased risk of neoplastic events after recombinant human growth hormone (rhGH) treatment in childhood has been an ongoing concern but long-term safety data are limited.Methods: A nationwide population-based cohort study in Sweden of patients treated with rhGH during childhood between 1985-2010, due to isolated growth hormone deficiency (GHD), small for gestational age (SGA) and idiopathic short stature (ISS). The comparison group consisted of 15 age-, sex-, and region-matched controls per patient, randomly selected from the general population. Data on neoplastic events and covariates, such as gestational age, birth weight, birth length, socioeconomic status, and height at study start, were collected through linkage with population-based registers. The cohort was followed for neoplastic events until the end of 2020.Results: 53,444 individuals (3,408 patients; 50,036 controls) were followed for up to 35 years, with a median follow-up of 19.8 years and a total of 1,050,977 person-years. Patients showed a moderately increased hazard ratio (HR) for neoplastic events overall compared to controls (HR 1.28, 95% CI: 1.12-1.46), but only significant for males (HR 1.39, 95% CI: 1.17-1.66) and not females (HR 1.15, 95% CI: 0.94-1.41). Longer treatment duration was associated with an increased HR, but no association was found between neoplastic events and mean or cumulative dose. No increased risk of malignant neoplasms was observed for the patients compared to matched controls (HR 0.91 95% CI: 0.66-1.26).Conclusion: No association was found between rhGH treatment during childhood for GHD, SGA, or ISS and malignant neoplastic events in early to mid-adulthood. A moderate increase in overall neoplastic events was observed due to an increased number of events in male patients.


  • untitled reply

    by Anders Tidblad, Lars Sävendahl

    In Reply We have with great interest read the letter by Malozowski and Lightbourne about our study1 on long-term cardiovascular morbidity in patients previously treated with childhood growth hormone (GH) and would, first of all, like to thank the authors for having taken interest in our study.1 However, we would also like to clarify some misconceptions. Malozowski and Lightbourne state as critical limitations that we have failed to account for short stature, information about height by sex, and other hormonal deficiencies. We disagree with this description because we have indeed taken these issues into account. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.


  • Open Access

    The history, physiology and treatment safety of growth hormone

    by Anders Tidblad

    Growth hormone treatment was introduced in the 1950s to address growth disturbances and metabolic abnormalities. Hundreds of thousands of children have been treated, with gradual expansion of treatment indications. From initially being offered only to patients with severe growth hormone deficiency, today many children are treated for conditions in which the associated short stature is not primarily thought to be due to deficient endogenous growth hormone secretion. This review discusses the history, physiology and safety of growth hormone treatment, with focus on the long‐term risks of mortality, cardiovascular morbidity and cancer. Conclusion: Continuous follow‐up is needed to increase our knowledge of the long‐term treatment safety.


  • Open Access

    Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity

    by Anders Tidblad, Matteo Bottai, Helle Kieler, Kerstin Albertsson-Wikland, Lars Sävendahl

    Treatment with recombinant human growth hormone (rhGH) has been in clinical use since 1985, with treatment indications now extending beyond growth hormone deficiency (GHD) to include an increasing number of conditions in which childhood short stature is not primarily due to deficient endogenous growth hormone secretion, such as small for gestational age (SGA) without catch-up growth or idiopathic short stature (ISS).1 Apart from regulating linear growth during childhood, growth hormone and its prime mediator, insulinlike growth factor 1, have several effects on the metabolism of fat, protein, and carbohydrates2 as well as on the cardiovascular system.3,4 Moreover, both excess levels of growth hormone and GHD have been associated with increased cardiovascular morbidity and mortality.5-7


  • Metabolic Effects of Growth Hormone Treatment in Short Prepubertal Children: A Double-Blinded Randomized Clinical Trial

    by Anders Tidblad, Jan Gustafsson, Claude Marcus, Martin Ritzén, Klas Ekström

    Introduction: Growth hormone (GH) is a central hormone for regulating linear growth during childhood and also highly involved in the metabolism of lipids, carbohydrates, and protein. However, few studies report on how treatment with GH during childhood influences metabolic parameters. Our aim was to investigate metabolic effects of different doses of GH in short children with GH peak levels in the low to normal range. Design: Thirty-five prepubertal short children (<−2.5 SDS), aged 7–10 years, with peak levels of GH between 7 and 14 μg/L during an arginine-insulin tolerance test, were randomized to 3 different doses (11/33/100 μg/kg/day) of GH treatment for 2 years. Auxological and metabolic investigations were performed. These included metabolites in blood and interstitial microdialysis fluid, dual-energy X-ray absorptiometry, frequently sampled intravenous glucose tolerance test (FSIVGTT), and stable isotope examinations of rates of glucose production and lipolysis. Results: At 24 months, the high-dose group (HD) had higher fasting insulin compared with the standard-dose (SD) and low-dose (LD) groups (HD: 111.7 vs. SD: 61.2 and LD: 46.0 pmol/L [p < 0.001]) and showed signs of insulin resistance (HOMA-IR, HD: 4.20 vs. SD: 2.17 and LD: 1.71 (LD) [p < 0.001]). The FSIVGTT also demonstrated higher acute insulin response (p < 0.05). Few other metabolic differences were found at 24 months, but a decreased insulin sensitivity index (Si) could already be seen at 12 months for both SD and HD compared with the LD group (p < 0.05). Conclusion: Treatment with GH resulted in a dose-dependent decrease in insulin sensitivity, demonstrated by higher levels of fasting insulin and signs of insulin resistance in both HOMA indices and FSIVGTT examinations.